Blockchain Registration Transaction Record

ABVC's BioKey Leads in Local Pharma Manufacturing Amid Global Shifts

ABVC BioPharma's BioKey subsidiary stands ready in Silicon Valley, offering a strategic U.S. pharmaceutical platform amid global tariff shifts and supply chain realignments.

This news is crucial for stakeholders in the pharmaceutical and biotech industries, especially those navigating the complexities of global supply chains and regulatory environments. ABVC BioPharma's strategic positioning of BioKey addresses the urgent need for resilient, transparent, and compliant drug development and production. With the U.S. imposing tariffs on Asian pharmaceutical imports and the CDMO market's rapid growth, BioKey's established infrastructure and expertise offer a competitive edge. For Asian biotech companies aiming to enter the U.S. market, BioKey provides a vital operational bridge, reducing barriers related to regulatory compliance, formulation transfer, and cultural differences. This development not only underscores the importance of local manufacturing in ensuring drug supply chain resilience but also highlights the growing trend towards trust-based localization in the pharmaceutical industry.